Rocket Aborts FDA Filing for Rare Blood Disease Gene Therapy

By /

Rocket Pharmaceuticals’ strategic realignment initiative in July pulled funding from fanca-cel, which the biotech was developing for Fanconi anemia.

Scroll to Top